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Abstract:  
Premalignant lesions have been identified in both the ductal and lobular units of the breast epithelium. 
These lesions have a 4-fold increase in risk of progression to invasive breast cancer, but 80% will remain 
indolent. This may be due, in part, to the uncertainty of diagnoses as inter-observer reproducibility is poor. 
When treated with prophylactic hormone therapies blocking the estrogen receptor, up to 40% of women still 
develop tumors. Therefore the challenge is to develop diagnostic tests that identify the subset of high-risk 
lesions and provide appropriate prophylactic therapies.  
We undertook genome-wide expression studies to define sets of genes that show reproducible 
alterations in atypical hyperplastic lesions. Patients with sporadic atypical hyperplasias and no evidence of 
breast cancer for at least 2 years following the initial biopsy were selected. RNA quality from formalin-fixed, 
paraffin-embedded (FFPE) was assessed using the ratio of 150 and 500 bp amplicons of B-actin 
determined by RT-qPCR. A total of 23 patients were included with diagnoses of pure flattened epithelial 
atypia (FEA, n=2), atypical lobular lesions (n=9), and atypical ductal lesions (n=12). The atypical lesions 
and histologically normal breast epithelium were microdissected separately from 6 um thick tissue sections 
from each patient. RNA was amplified linearly, labeled and hybridized to Affymetrix ST1.0 arrays. Genes 
differentially expressed by >2-fold between the lesion and normal epithlium within each patient were used 
to identify gene expression signatures of atypical hyperplasias. Hierarchical clustering of a 512 gene 
signature yielded 3 major groupings: Benign, Intermediate, Atypia. These results reveal that atypia of the 
lobular and ductal structures share common underlying transcriptional features. The gene profile provides 
markers that can improve the reproducibility of diagnoses of atypia. Expression profiling of individuals who 
subsequently progress to invasive carcinoma will provide biomarkers of high-risk premalignancies and 
assist selection of therapeutic choices. 
  
